CEL-SCI Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vaccine at Conference
February 21 2017 - 8:45AM
Business Wire
CEL-SCI Corporation (NYSE MKT:CVM) today
announced that Dr. Daniel Zimmerman, its Senior V.P of Research,
Cellular Immunology, presented data with a LEAPS Rheumatoid
Arthritis therapeutic (treatment) vaccine at Madridge‘s
International Conference on Vaccines held in Baltimore, MD on
February 20-22, 2017.
At the conference Dr. Zimmerman presented a potentially novel
approach to fighting the inflammation in the joints caused by
Rheumatoid Arthritis. He introduced animal data that demonstrates
that using CEL-SCI’s L.E.A.P.S CEL-4000 Rheumatoid Arthritis
treatment vaccine downregulates pro-inflammatory T-cell responses
and upregulates anti-inflammatory T-cell responses. This finding
was confirmed by an examination of cytokines in the serum of the
animals.
This demonstrates that LEAPS CEL-4000 has the potential for use
as a therapeutic vaccine to treat certain types of Rheumatoid
Arthritis if these results can be confirmed in human studies. The
study was conducted in collaboration with Dr. Tibor Glant's
research team at Rush University Medical Center. Dr. Glant holds
the "Jorge O. Galante, MD" Endowed Chair Professorship in
Orthopedic Surgery at Rush.
The Proteoglycan induced arthritis (PGIA) animal model was
developed and has been studied extensively in Dr. Glant's
laboratory at Rush University Medical Center for over 25 years and
is considered to be closely related to the human condition of many
Rheumatoid Arthritis patients. The PGIA model exhibits rheumatoid
factor (Rf) and Rheumatoid Arthritis -specific antibodies not seen
in other Rheumatoid Arthritis models.
The LEAPS vaccines in this preliminary study consisted of a
disease epitope (portion of a disease associated antigen protein)
attached to a portion of another very small peptide immune cell
binding ligand (ICBL) chosen to promote and direct the immune
response away from a Th1 response. When the ICBL and the
disease-related Proteoglycan epitope were conjugated to each other,
one of the LEAPS vaccines promoted protective immune responses
reduced arthritis symptoms in the animals.
Rheumatoid arthritis is a chronic inflammatory disease that
mainly targets the synovial membrane, cartilage and bone. It
affects about 1% of the global population and is associated with
significant morbidity and increased mortality.
About CEL-SCI
CEL-SCI's work is focused on finding the best way to activate
the immune system to fight cancer and infectious diseases. The
Company has operations in Vienna, Virginia, and in/near Baltimore,
Maryland.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. When used in this press release, the words "intends,"
"believes," "anticipated," "plans" and "expects," and similar
expressions, are intended to identify forward-looking statements.
Such statements are subject to risks and uncertainties that could
cause actual results to differ materially from those projected.
Factors that could cause or contribute to such differences include,
an inability to duplicate the clinical results demonstrated in
clinical studies, timely development of any potential products that
can be shown to be safe and effective, receiving necessary
regulatory approvals, difficulties in manufacturing any of the
Company's potential products, inability to raise the necessary
capital and the risk factors set forth from time to time in
CEL-SCI's filings with the Securities and Exchange Commission,
including but not limited to its report on Form 10-K and 10-K/A for
the year ended September 30, 2016. The Company undertakes no
obligation to publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170221005661/en/
CEL-SCI CorporationGavin de Windt, 703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2023 to Apr 2024